
Copper intra-uterine contraceptive devices - Contraception
You are here : Home > Formulary Search > Copper intra-uterine contraceptive devices - Contraception
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Intrauterine device (copper)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Preferred
Copper T380 A®
Status 2
Green
Formulations :
- Intrauterine device (copper)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Nova T 380
Status 3
Green
Formulations :
- Intrauterine device (copper)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Preferred
T-Safe 380A QL
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Copper intra-uterine contraceptive devices
Indication :
Contraception
Group Name :
Keywords :
coil
Brand Names Include :
Copper T380 A®, T-Safe® 380A QL, Nova T 380
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3
Other Indications
Below are listed other indications that Copper intra-uterine contraceptive devices is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Contraception.
- Desogestrel
- Dienogest with estradiol valerate
- Drospirenone
- Drospirenone with estetrol
- Estetrol and drospirenone
- Estradiol with nomegestrol
- Ethinylestradiol with desogestrel
- Ethinylestradiol with drospirenone
- Ethinylestradiol with etonogestrel
- Ethinylestradiol with gestodene
- Ethinylestradiol with levonorgestrel
- Ethinylestradiol with norelgestromin
- Ethinylestradiol with norethisterone
- Etonogestrel
- Levonorgestrel
- Medroxyprogesterone acetate
- Norethisterone
- Norethisterone with mestranol
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.